StockNews.AI
SCPX
StockNews.AI
214 days

Scorpius Holdings Cancels Planned Reverse Stock Split

1. Scorpius Holdings cancels planned 1-for-20 reverse stock split. 2. No reverse stock split may signal stability in SCPX stock. 3. Scorpius focuses on biologics with advanced facilities in Texas. 4. Company emphasizes transparency and collaboration in biomanufacturing.

-21.28%Current Return
VS
-0.1%S&P 500
$0.4701/17 03:14 PM EDTEvent Start

$0.3701/20 03:28 PM EDTLatest Updated
3m saved
Insight
Article

FAQ

Why Bullish?

Canceling a reverse split often indicates a management decision to maintain shareholder value. Past examples show stocks can rally after avoiding dilution via reverse splits.

How important is it?

The decision to cancel a reverse stock split has significant implications for shareholder confidence and future investment. It reflects management's strategic plan for stock price stabilization.

Why Short Term?

Immediate effects on stock sentiment are likely, but long-term performance depends on operational results. Stocks often react quickly to such corporate actions.

Related Companies

January 17, 2025 15:13 ET  | Source: Scorpius Holdings, Inc. DURHAM, N.C., Jan. 17, 2025 (GLOBE NEWSWIRE) -- Scorpius Holdings, Inc (NYSE American: SCPX) (“Scorpius” or “the Company”), an integrated contract development and manufacturing organization (“CDMO”), today announced that the Company’s planned 1-for-20 reverse stock split (the “Reverse Stock Split”) of its common stock (the “Common Stock”) that was announced yesterday, will not be effectuated. Scorpius Holdings, Inc. Scorpius Holdings, Inc. is an integrated contract development and manufacturing organization (CDMO) focused on rapidly advancing biologic programs to the clinic and beyond. Scorpius offers a broad array of analytical testing, process development, and manufacturing services to pharmaceutical and biotech companies at its state-of-the-art facilities in San Antonio, TX. With an experienced team and new, purpose-built U.S. facilities, Scorpius is dedicated to transparent collaboration and flexible, high-quality biologics biomanufacturing. For more information, please visit www.scorpiusbiologics.com. Media and Investor Relations ContactDavid Waldman+1 919 289 4017ir@scorpiusbiologics.com

Related News